Efficacy evaluation of intracervical lymph node immunotherapy (ICLIT) in children with allergic rhinitis and allergic rhinitis complicated with asthma.

BACKGROUND

Intracervical lymph node immunotherapy (ICLIT) has demonstrated favorable short-term efficacy and safety in children with allergic rhinitis (AR). However, its efficacy in children with AR complicated by asthma (AR+AA) remain studied.

AIMS/

OBJECTIVES

To evaluate the validity of ICLIT in children with AR+AA.

MATERIAL AND

METHODS

Thirty children were enrolled, with 15 in AR group and 15 in AR+AA group. All patients received ICLIT. Total nasal symptom score (TNSS), total ocular symptom score (TOSS), and rhinoconjunctivitis quality of life questionnaire (RQLQ) were assessed at baseline and 3, 6 and 12 months post-treatment. The AR+AA group additionally completed the asthma control questionnaire (ACQ-6) and pediatric asthma quality of life questionnaire (PAQLQ). IgE were measured too.

RESULTS

After 12 months of treatment, both groups showed significant improvements from baseline in TNSS, TOSS, and RQLQ (all p < 0.05). However, the magnitude of improvement did not differ significantly between groups (all p > 0.05). In the AR+AA group, ACQ-6 scores decreased from 1.81 ± 1.32 at baseline to 0.51 ± 1.21 (p < 0.001). Serum total IgE and dust mite-specific IgE levels significantly decreased from baseline in both groups (p < 0.05).

CONCLUSIONS AND SIGNIFICANCE: ICLIT effectively improves symptoms and quality of life in children with both isolated AR and AR+AA.